Pancreatic insufficiency affects 85-90% of patients with cystic fibrosis and is the main cause of their intestinal malabsorption.' This results in high energy losses in the stools,2 which, together with reduced intake and an increased energy expenditure,3 4 may compromise the patient's nutritional state and prognosis.5 6 Many patients experienced an impressive improvement in their symptoms in intestinal malabsorption when they changed from the traditional pancreatic extracts to acid resistant microspheres. Also, many were then able to tolerate a normal or even generous fat intake, thus improving their total energy intake. 7 The improved absorption of fat and nitrogen after the change to the acid resistant microspheres is well documented. 8'0 There are, however, many patients who require large doses of an acid resistant microsphere preparation (either Creon, Duphar; Pancrease, Cilag; or Nutrizym GR, Merck) to achieve reasonable control of fat malabsorption as judged by their symptoms, or, more commonly, by an acceptable coefficient of fat absorption (absorption of more than 85% of ingested fat). In a few patients adequate fat absorption is not achieved.
The purpose is this trial was to determine whether control of malabsorption could be maintained when the same dose of pancreatic enzyme was supplied in a high lipase preparation as in a standard acid resistant microsphere preparation. If 
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